AACE: Ralph A. DeFronzo, MD -- Diabetes Prevention Supports More Aggressive and Earlier Intervention
Dr. DeFronzo presented the "Diabetes Update - 2013," focusing on preventing diabetes....
Positive Results for Next Once A Week GLP-1
Five studies show positive results for new GLP-1 drug dulaglutide....
Incretin Therapy in Combination with Insulin for Type 2 Diabetes Patients
Incretin-based therapies are an intuitive option for adjuvant therapy with insulin due to….
Diabetes Meds Can Cut Heart Failure Risk by 41%
People with diabetes who are taking certain antidiabetic medications may also be taking care of their heart....
Incretin Mimetics and Risk of Pancreatic Cancer?
FDA has launched an investigation on an unpublished study suggesting that incretin mimetics are associated with pancreatic cancer....
Patients Using GLP-1 Are More than 40 Percent Less Likely to be Hospitalized for Heart Failure
In the retrospective study, researchers from Henry Ford Hospital in Detroit examined data from more than 4,400 patients taking diabetes medications between 2000 and 2012....
Next Once-Daily GLP-1 Agonist, Lixisenatide, Approved in EU
One more GLP-1 agonist gets approved in Europe....
GLP-1 Agonists May Be Effective for Obese Adolescents
Preliminary evidence from a clinical trial suggests that treatment with GLP-1 receptor agonists was associated with….
Liraglutide Safe for Type 2's with Liver Injury
Treatment with liraglutide 1.8 mg for 26 weeks was well tolerated and improved liver enzymes in type 2 diabetes patients....
Adverse Events Rule Out Taspoglutide in Diabetes Patients
Successful studies can help to determine how new products can help in improving lives. But, studies that are not successful can provide information also....
Baseline A1C Can Be a Predictor of Response to GLP-1 Treatments
Are patients with a higher baseline A1C more likely to have a better glycemic response to GLP-1 treatments?...
SPECIAL FEATURE ARTICLE: The Effects of GLP-1 Agonists -- A Review of the Drug Class
Amanda Zell, PharmD Candidate, Mercer University College of Pharmacy
Glucagon-like peptide-1 (GLP-1) is part of a family of peptide hormones known as incretins.
GLP-1 Analogs, Appetite and Satiety
Cierra Harden PharmD Candidate 2013 LECOM School of Pharmacy, Bradenton
Obesity is a major risk factor for the development of diabetes as well as predisposing individuals to hypertension...
The Use of GLP-1 Analogs and Lifestyle Changes
Alan Mathis PharmD Candidate 2013 University of Florida
GLP-1 analogs not only improve plasma glucose levels and reduce HbA1c, but also improve metabolic effects such as reduction in...
GLP-1 Agonists and Lifestyle Changes: A Recipe for Success
Andre McMahon, PharmD Candidate UF College of Pharmacy
Achieving glycemic control is a critical goal in the management of patients with type 2 diabetes mellitus (DM).
GLP-1 Agonist Effects on Glucagon Suppression
Alan Mathis, PharmD Candidate 2013, University of Florida College of Pharmacy
The pathophysiology of type-2 diabetes is characterized by insulin resistance and beta-cell...
Glycemic Efficacy of GLP-1 Receptor Agonists
What are the results after adding a GLP-1 receptor agonist to the treatment of type 2 patients after 30+ weeks of treatment?...
Liraglutide Shows Decreased BMI and Waist Circumference
New data is showing a decrease in waist circumference in patients with type 2 diabetes treated with liraglutide and correlates with positive alterations in inflammatory markers....
The Effects of GLP-1 on Cardiovascular Health
Tina Burge, Doctor of Pharmacy Candidate, FAMU College of Pharmacy
Reviewed by Dave Joffe, BSPharm, CDE
It's well-known...
Incretin Effect Independent of Glycemia Level
Healthy individuals without diabetes have similar increases in insulin secretion....
Linagliptin Noninferior to Glimepiride in Diabetes Patients Failing Metformin
Two-year results suggest that the use of the DPP-4 inhibitor linagliptin is as effective as glimepiride in treating diabetic patients who are inadequately controlled with metformin....
Insulin with Liraglutide Improves Poorly Controlled Type 1
Obese adults with poorly controlled type 1 diabetes can better control their blood sugar by adding liraglutide to their insulin therapy....
GLP-1: Actions on Beta-cell Mass and Function
David Joffe, BSPharm, CDE
Tina Burge, PharmD Candidate Florida A&M University
AACE: Liraglutide Shows Positive Results in Head to Head Study
Patients more likely to reach A1c target at any given time during 26 weeks' treatment with liraglutide compared with both sitagliptin and exenatide....
GLP-1 Agonists: Increasing Effective Insulin Release
By Wael Diab, RPh, PharmD Candidate University of Colorado College of Pharmacy
The pathophysiology of type 2 diabetes mellitus is complex, consisting of far more physiologic defects than simple...
One Year Study Showed a 36% Loss in Excess Body Weight
Obese individuals completed a 1-year study and lost a mean 35.6% of excess body weight taking….
An Educator's Perspective: Janet Carson, R.N., C.D.E., Largo, FL
Often times there can be difficulty getting approval for the patient to use a GLP-1 analog and so the patient may miss a few days of the medication and possibly decide they don't want to continue. I have gotten in the habit of ordering the...
A Primary Care Physician's Perspective: Dr. Norris Brown, Austin, TX
When the GLP-1 analogs first came out I was slow to start using them. As a primary care physician in a busy multi-practitioner office I was used to working with oral medications for diabetes, and only as a last resort would I put patients on...
A Nurse's Perspective: Martha M. Funnell, MS, RN, CDE
In our practice we spend time in the community and encounter patients who are seeing primary care physicians and are on minimal therapy as well as patients from our clinic who are managed more aggressively....
Physicians' Perspective: Gregory Peterson, MD, and Craig Spellman, MD
Gregory Peterson and Craig Spellman are two physicians who see a lot of diabetes patients in their practices, and are very familiar with the use of GLP-1 agonists. Both of them have written journal articles about the use of these newer...
An Educator's Perspective: Michelle Laine, A.R.N.P., C.D.E.
Most of my colleagues wait till their patients are maxed out on oral medications -- often this means that they are on 3 or 4 medications without achieving control, before starting them on either basal insulin or GLP-1 analogs....
A Pharmacist's Perspective: Stuart T. Haines, PharmD, FCCP, FASHP, FAPhA
Patient Education and Monitoring Recommendations for the Use of GLP-1's
Unlike most diseases, diabetes requires extensive patient...
GLP-1 and Appetite Suppression
There has been an increased use of GLP-1 analogs in patients with diabetes over the past two years as the advent of daily dosing has made medication adherence simpler and more clinicians are comfortable with the available choices.
GLP-1 a Good Choice for Glycemic Control?
The top three drugs for the reduction of A1c levels are biphasic insulin, glucagon-like peptide 1 (GLP-1) analogs, and….
Lixisenatide Once-Daily GLP-1 Drug Effective for Type 2 Diabetes
Monotherapy with the investigational GLP-1 receptor antagonist lixisenatide significantly reduces postprandial glucose excursions and HbA1c in treatment-naive type 2 diabetes patients....
Short-term Effects of Liraglutide on Visceral Fat Adiposity, Appetite, and Food Preference
Short-term treatment with liraglutide improved visceral fat adiposity, appetite, food preference and the urge for fat intake in obese Japanese patients with type 2 diabetes....
Appetite-curbing Hormone Helps to Lose Weight
Obese patients with or without diabetes who took a minimum dosage of the appetite-suppressing glucagon-like peptide-1 hormone for at least 20 weeks lost more weight than people in control groups from a review of 25 studies in the British Medical...
GLP-1 Help to Control Diabetes after Gastric Bypass
Insulin, glucagon-like peptide-1 positively linked in diabetes patients following gastric bypass surgery....
SPECIAL FEATURE: Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
The regulation of food intake is a complex process involving psychologic, social, and physiologic components. Physiologically, it is generally assumed that food intake is regulated by a central feeding drive that is later counterregulated by...
SPECIAL FEATURE: GLP-1 Agonist-based Therapies: An Emerging New Class of Antidiabetic Drug With Potential Cardioprotective Effects
Melanie Sulistio, MD, Curtis Carothers, MD, Mandeep Mange, BS, Mike Lujan, BS, Rene Ofiveros, MD, and Robert Chilton, DO
PART 2: GLP 1 Agonist-based Therapies: How do they reduce...
GLP-1 Agonist-based Therapies: An Emerging New Class of Antidiabetic Drug With Potential Cardioprotective Effects, Part 1
Melanie Sulistio, MD, Curtis Carothers, MD, Mandeep Mange, BS, Mike Lujan, BS, Rene Ofiveros, MD, and Robert Chilton, DO
Cardiovascular disease is a leading cause of death in the...
EASD: Liraglutide Plus Insulin Does Not Add Weight
The addition of insulin to the treatment regimen of type 2 diabetes patients on liraglutide (Victoza) doesn't wipe out previously seen weight loss, and insulin also appears to help these patients achieve glycemic control, researchers...
Significant Weight Loss Observed in Nondiabetic Obese Women Treated with Exenatide
Exenatide, a glucagon-like peptide-1 (GLP-1) agonist was associated with significant weight loss in obese women who were not diabetic, according to research....
The Safety and Extrapancreatic effects of GLP-1 on cardiovascular tissue, adipose tissue, liver, and kidney
GLP-1 receptors are widely expressed in CV, adipose, hepatic, and renal tissue. High-affinity GLP-1 receptors are present in autonomic nuclei that control CV functions, and have been isolated in rodent and human cardiomyocytes, endothelial...
GLP-1 Lixisenatide Phase III Results
Adding lixisenatide to metformin and insulin glargine significantly reduced glycated hemoglobin levels and improved post-prandial glucose in patients with type 2 diabetes....
GLP-1's Function in Preserving B-cells
Associations between acute glucose lowering and improved acute insulin secretory responses suggest improved β-cell function. Comparing and assessing effects of pharmacological therapies used to control hyperglycemia on β-cell...
Diabetes Drug Also Reduces Inflammation
A GLP-1 drug prescribed to help patients with type 2 diabetes improve blood-sugar control also has a powerful anti-inflammatory effect, and the effect was observed within 2 hours following a single dose....
EASD: First Injection-free Once-A-Year GLP-1
ITCA 650, injection-free continuous delivery of GLP-1 therapy, demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI AEs typically associated with this...
GLP-1 Special Series Bonus Issue Editor's Desk
We are all familiar with the phrase, "Save the Best for Last," and as we finish up our special GLP-1 Series, we have done exactly that.
This week we have the completion of an interview that our publisher, Steve Freed,...
GLP-1 Special Series Issue #8 Editor's Note
If you do enough interviews you are bound to get a few great ones. Often when we talk to researchers they either hold back on information that they are afraid to share or they try to be experts on everything we ask them. Our publisher, Steve...
Lilly Prepares to Launch Bydureon in US
Eli Lilly aims to bring its once-a-week diabetes injection Bydureon to US markets in the first half of next year....
GLP-1 Special Series Editor's Note #7
There's been some interesting research on a compound that appears to be a partner peptide for GLP-1. Oxyntomodulin is released in response to a meal and seems to have a significant effect on glucose levels. Our current PharmD candidate, ...
Liraglutide Shows Potential as Treatment for Weight Loss in Non-Diabetics
Liraglutide, recently approved in the US for the treatment of type 2 diabetes, has demonstrated its potential as a weight-loss drug for nondiabetic, obese patients....
GLP-1 Special Series Editor's Note #6
This week we get back to our interview with Dr. Aaron Vinik, Director, EVMS Strelitz Diabetes Research Center. He has been at the forefront in developing new technologies for growing and regenerating beta cells. Our publisher, Steve...
Interview with Aaron I. Vinik, MD, PhD, FCP, MACP
One of the leading diabetes researchers in the world, Dr. Aaron I. Vinik leads the EVMS Strelitz Diabetes Center's quest to cure diabetes. Internationally renowned for his research in the areas of hormone secreting tumors and the chronic...
GLP-1 Knowledge Survey Part II
We asked our readers to give us feedback into how much they knew about GLP-1 Analogs and a broad cross-section replied. Take a look at 5 of the questions and how your colleagues answered....
Dr. Vinik Answers Our Best Questions on GLP-1 Therapy
This week, after our publisher Steve Freed was able to connect up with Dr. Vinik again,...
ADA: Liraglutide Shows Potential as Treatment for Weight Loss
Liraglutide, recently approved in the United States for the treatment of type 2 diabetes, has demonstrated its potential as a weight-loss drug for nondiabetic, obese patients....
GLP-1 Special Series #5 Editor's Note
This week in Part 3 of our Case Study, Mr. Walker and his wife return for a follow-up visit as his glucose control has not improved as much as expected.
Type 2 Drug Liraglutide Evens Glucose Levels, Lowers Insulin Needs in Type 1 Diabetes
By themselves, insulin-based treatments do not adequately control glycemic variations (or excursions) in type 1 diabetes in a consistent fashion....
GLP-1 Special Issue #4 Editor's Note
Steve and Andrew came back with a ton of new data on GLP-1 Agonist therapies from the 71st Scientific Sessions of the ADA. We turned over these articles, abstracts, posters and presentations to our interns for them to get...
FDA Warns Healthcare Professionals to Closely Monitor Patients with Diabetes Receiving Liraglutide Injections
The US Food and Drug Administration (FDA) warned healthcare professionals to closely monitor patients with diabetes receiving liraglutide injections (Victoza, Novo Nordisk) for thyroid C-cell tumors and acute pancreatitis....
GLP-1 Issue #3 Editor's Note
This week we have the results from our GLP-1 Survey. Thanks to the great number of you who participated, and congratulations to Dr. Donald W., of Southern Pines, North Carolina, the winner of our Kindle/Nook giveaway....
Interview with Aaron I. Vinik, MD, PhD, FCP, MACP
One of the leading diabetes researchers in the world, Dr. Aaron I. Vinik leads the EVMS...
GLP-1 Editor's Note:
This week I had a chance to interview Dr. Vivian Fonseca on the use of GLP-1 agonists, and he shared his thoughts on why these medications are a logical choice. He also gave us a little information on a study using GLP-1 agonists with...
The Incretin Effect
For the complete article, The Incretin Effect, and information on other aspects of GLP-1 treatment, please visit Novo Nordisk's diabetesinamerica at
GLP-1 Notes from the Editor
Welcome to our first edition of our new GLP-1 education series. I am sure that every one of you is familiar with the use of GLP-1 agonists in the treatment of diabetes.
Ever since Bayliss and Starling discovered secretin...
Sanofi's Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study
Lyxumia (lixisenatide) when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes...
Can Liraglutide Antibodies Affect Its Efficacy?
Researchers looked at antibody formation when liraglutide (Victoza) is used and whether that has an impact on glycemic efficacy or safety....
Next GLP-1 (Lixisenatide) Achieves Positive Phase III Data in Type 2 Diabetes
Once-Daily Lixisenatide meets primary efficacy endpoint with fewer hypoglycemias than Exenatide twice-daily....
Editor's Note: GLP-1 Agonists, ID Bracelets and More Great Slides
After Andrew left the JPMorgan Meeting in San Francisco we spoke about the near future of diabetes care for Type 2 patients and he said he thought it will be in GLP-1 agonist therapy. With over 16 new GLP-1s in second or third phase development it...
Transdermal GLP-1 Patch for Type 2 Diabetes
TransPharma Medical, Ltd., announced the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of Type 2 diabetes....
Roche Suspends Dosing in Drug Trials for Its GLP-1 Compound
A higher rate of hypersensitivity and GI intolerability was seen with taspoglutide…
ADA: Switching to Liraglutide from Exenatide Improves Glycemic Control
Conversion from exenatide to liraglutide is well tolerated and provides additional glycemic control and cardiometabolic benefits....
GLP-1 Once-Weekly Analogue Taspoglutide Found Safe and Effective
Taspoglutide demonstrates superiority in HbA1c change versus placebo as add-on to metformin and pioglitazone....
Positive Phase III Diabetes Data with a New GLP-1 Cpd
Sanofi-aventis announced the positive results of the first, placebo-controlled study of the GetGoal Phase III clinical trial program with lixisenatide, a novel, once daily GLP-1 agonist, for the treatment of Type-2 diabetes...
Once-Daily Victoza® Improves Blood Sugar over Exenatide
Published results from the LEAD 6 extension study showed the efficacy and safety of switching from exenatide, taken twice a day, to once-daily Victoza®. Results show...
Switching to Once-Daily Victoza(R) (Liraglutide) from Exenatide Further Improves Blood Sugar Control in Patients with Type 2 Diabetes
Diabetes Care has published online the results of the Novo Nordisk (NVO) LEAD™ 6 extension study....
Two Year Update: Liraglutide Patients Lose 5% of Their Body Weight
A 2-year update of a trial comparing liraglutide with a sulfonylurea in patients with Type 2 diabetes demonstrates that liraglutide continues to control hyperglycemia better than a sulfonylurea without increasing the risk for...
Liraglutide Lowered Blood Sugar and Weight in Type 2 Diabetes
Novo Nordisk data presented last week, showed that when taken by itself, once-daily liraglutide, an investigational treatment for Type 2 diabetes, leads to statistically significant and sustained reductions in blood sugar and weight in African...
GLP-1 Knowledge Survey Part I
This week we have some results from our GLP-1 survey. Thanks to the great number of you who participated. As we put together the original survey our first thoughts were to find out what you wanted to know about GLP-1 analogs and...
ADA - Liraglutide Reverses Prediabetes 90%
Researchers at the ADA reported that Liraglutide reverses prediabetes indices in most obese patients with existing prediabetes …Full Story
ADA - GLP-1 Liraglutide Versus Sulfonylureas
Novo Nordisk experimental diabetes drug liraglutide was significantly better at helping patients control blood sugar than an older common medicine after two years of treatment, according to data from a clinical trial.
CHMP Recommends Approval of Novo Nordisk's Victoza(R) (Liraglutide) for Type 2 Diabetes
Novo Nordisk announces that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMEA) adopted a positive opinion, recommending marketing authorization, for Victoza® for the treatment of Type 2...
Liraglutide Has Low CVD Risk but May Be Blocked for Approval
Tumor data may block approval for diabetes drug liraglutide. An FDA advisory panel declined to recommend approval for the investigational diabetes drug liraglutide (Victoza), in light of
Liraglutide Combination Effective in Type 2 Diabetes
In patients with type 2 diabetes being treated with metformin, the addition of the glucagon-like peptide-1 analog liraglutide is as effective as glimepiride in improving glycemic control but with less weight gain, researchers report.
Liraglutide Controls Glucose, Promotes Weight Loss in Type 2 Diabetes
Liraglutide appears to control glucose levels as well as does glimepiride when given with metformin, with the added benefit of weight loss, a new phase III trial has concluded.
Head-to-Head Phase 3 Trial of Exenatide and Liraglutide
In a head to head trial (LEAD 6), it showed that liraglutide, a human GLP-1 analog administered once daily was significantly more effective at improving blood glucose control (as measured by HbA1c) than exenatide, a GLP-1 mimetic administered twice...
Liraglutide Diabetes Drug Works Well in Trial and Expected Approval Early 2009
The once a day drug, liraglutide, is a laboratory-made version of glucagon-like peptide-1 (GLP-1), a hormone produced by the body. Several members of the GLP-1 family are in clinical trials, and one (Byetta) already has been approved by the U.S....
Liraglutide Study For Weight Loss To Begin
Denmark's Novo Nordisk, the world's biggest maker of insulin, on Friday said it expected to start a Phase III trial for its drug candidate liraglutide in obesity before the end of this year.
EASD: Incretin Mimetic Liraglutide When Added, Boosts Glycemic Control
Type 2 diabetes patients given daily injections of investigational liraglutide atop oral metformin and rosiglitazone (Avandia) achieved significant reductions in plasma glucose by a drop in A1c of 1.5%, with lower blood pressures and weight loss,...
ADA: Investigational Diabetes Drug Liraglutide Sheds Fat
Weight loss with the investigational incretin analog liraglutide targets fat mass preferentially over muscle, Swedish researchers found.
Significant Weight Loss With Liraglutide
Novo Nordisk announces results of a phase II clinical trial for liraglutide, which shows significant weight loss in obese people.
New Drug Liraglutide Is Promising in Type 2 Diabetes Treatment
Liraglutide a long-acting glucagons-like peptide 1 improved glycemic control in Type 2 diabetes without weight gain.
Issue 97 Item 3 Item #3 Revisited from July 17, 2001, Issue 61. See current upda
New Amazing Treatment for Type 2 Diabetes –July 17,2001
Issue 95 Item 10 Another Treatment Option Glucagon-like Peptide 1 (GLP-1) Lookin
May turn out to be beneficial for the treatment of type 2 diabetes.
Editor's Desk: Getting Your Patients on Track with GLP-1s
I am often in a position to recommend the selection of medications for the patients with type 2 diabetes who I see in prescribers' offices.
Most medical practitioners will make metformin their first choice as this has...
Perspectives from Diabetes Thought Leaders on the Use of GLP-1 Agonists
To help introduce this new series on GLP-1 therapy, we've gathered together commentary and insight from leading experts across the field: Anne L. Peters, MD, Ralph A. DeFronzo, MD, Alan J. Garber, MD, PhD, Robert R. Henry, MD, Richard...
Diabetes Update, Part 3 of 3
In this week's series of Homerun Slides, we review the insulin analogs, the principles of...
Diabetes Update, Part 2 of 3
In this week's Homerun Slides series, we go over why there is so much interest in the...
GLP-1 Agonists and Cardiovascular Health, Part 1 of 2
If you missed our Special Edition two weeks ago on
GLP-1 Agonists and Cardiovascular Health
For this Special Edition series of Homerun Slides, we're focusing on the cardio-protective aspects of...
Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 2 of 2
Part 2 of our short series on some of the newer diabetes therapies inludes a glance at some of what is...
Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2
Part 1 of this two-part series covers some of the newest therapies for type 2 diabetes including GLP-1...
Incretins, Part 7 of 7
This week, we wrap up our seven part series of Homerun Slides on Incretins with a...
Incretins, Part 6 of 7
This week's slide set includes slides on GLP-1 and the Central Nervous System, the Cardiac...
Incretins, Part 5 of 7
In this week's Homerun Slides, Incretins, Part 5 of 6, we review the tissue-specific...
Incretins, Part 4 of 7
In this week's Homerun Slides, we cover DPP-IV inhibitors including a comparison of...
Incretins, Part 3 of 7
This week we continue our six part series on Incretins with Homerun Slides...
Incretins, Part 2 of 7
This week with Part 2 of our new Incretins series of Homerun Slides, we cover...
Incretins, Part 1 of 7
This first of seven sets of Homerun Slides begins with GLP-1 physiology, then...
Pathophysiology in the Treatment of Type 2 Diabetes: Newer Agents, Part 5 of 5
This week we conclude our five-part series of Homerun Slides on Pathophysiology in the...
Pathophysiology in the Treatment of Type 2 Diabetes: Newer Agents, Part 4 of 5
This week we continue with Part 4 of our series of Homerun Slides on...
Pathophysiology in the Treatment of Type 2 Diabetes: Newer Agents, Part 3 of 5
We continue this week with our
Pathophysiology in the Treatment of Type 2 Diabetes: Newer Agents, Part 2 of 5
This week we continue our series of Homerun Slides on Pathophysiology in the...
Pathophysiology in the Treatment of Type 2 Diabetes: Newer Agents, Part 1 of 5
This week we begin a new five-part Homerun Slides series on Pathophysiology in the...
GLP-1 Effectiveness, Mechanisms of Action and Potential, Part 4 of 4
This week we wrap-up our four part series on GLP-1 Agonists. Topics covered this week...
GLP-1 Effectiveness, Mechanisms of Action and Potential, Part 3 of 4
This week, we present Part 3 of a series of 4 Homerun Slide...
GLP-1 Effectiveness, Mechanisms of Action and Potential, Part 2 of 4
This week, we continue with Part 2 of our Homerun Slides series on...
GLP-1 Effectiveness, Mechanisms of Action and Potential, Part 1 of 4
Topics covered include the clinical effects of GLP-1 agonists and DPP-4 inhibitors stemming...
